AstraZeneca (AZN) Receives “Equal weight” Rating from Morgan Stanley
Morgan Stanley reiterated their equal weight rating on shares of AstraZeneca (LON:AZN) in a research report report published on Friday. Morgan Stanley currently has a GBX 5,000 ($66.96) target price on the biopharmaceutical company’s stock.
Several other analysts have also recently weighed in on the stock. Citigroup reaffirmed a buy rating on shares of AstraZeneca in a report on Thursday, September 7th. Barclays set a GBX 6,300 ($84.37) target price on shares of AstraZeneca and gave the company a buy rating in a report on Wednesday, September 13th. Goldman Sachs Group reaffirmed a sell rating and issued a GBX 3,800 ($50.89) target price on shares of AstraZeneca in a report on Tuesday, October 17th. Liberum Capital reaffirmed a buy rating and issued a GBX 4,800 ($64.28) target price on shares of AstraZeneca in a report on Tuesday, September 5th. Finally, Natixis raised shares of AstraZeneca from a neutral rating to a buy rating and raised their target price for the company from GBX 5,000 ($66.96) to GBX 5,738 ($76.84) in a report on Wednesday, September 6th. Four research analysts have rated the stock with a sell rating, seven have issued a hold rating and twelve have issued a buy rating to the company’s stock. The stock currently has an average rating of Hold and a consensus target price of GBX 5,164.45 ($69.16).
Shares of AstraZeneca (LON AZN) traded up GBX 3.36 ($0.04) during trading hours on Friday, reaching GBX 4,780.36 ($64.02). 1,860,000 shares of the company traded hands, compared to its average volume of 2,180,000. AstraZeneca has a 52-week low of GBX 3,996 ($53.52) and a 52-week high of GBX 5,520 ($73.93).
AstraZeneca Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca PLC and related companies with MarketBeat.com's FREE daily email newsletter.